1862 John Wyeth & Brother publishes its first catalog, advertising elixirs and tonics.

1870s First exports of Wyeth products begin with shipments to England and Canada.

1877 The Wyeths coin the term "compressed tablets" and receive a trademark on the phrase.

1883 First foreign Wyeth facility is opened in Montreal.

1889 A fire breaks out and destroys the building at 1410 Walnut Street, where John Wyeth & Brother was located. A new store is built at 18th and Walnut Streets.

1907 With John Wyeth's death, his son, Stuart, inherits the firm and Frank Wyeth remains vice president.

1913 Frank Wyeth dies.

1925 Ayerst, McKenna & Harrison Ltd. is founded in Canada.

1926 American Home Products (AHP) is founded.

1929 Upon his death, Stuart Wyeth leaves the firm's controlling interest to his alma mater, Harvard University.

1929 AHP acquires The Bovinine Company, Incorporated.

1931 AHP buys Wyeth from Harvard University.

1931 AHP purchases Petrolagar Laboratories.

1939 Wyeth makes possible one of the first medical films, titled "Peptic Ulcer," by giving a grant to the Department of Gastroenterology of the Lahey Clinic in Boston.

1940 AHP acquires Reichel Laboratories.

1942 Ayerst Laboratories introduces Premarin® (conjugated estrogens tablets, USP), the world's first conjugated estrogens product, in the U.S. and Canada. Today, Premarin is the most widely prescribed estrogen product in the United States. (Please see Important Warning and Prescribing Information.)

1942 The U.S. Navy bestows the much-coveted Army-Navy E Award upon Wyeth, establishing it as one of the first pharmaceutical companies to receive such an honor.

1943 Ayerst Laboratories joins AHP.

1943 John Wyeth & Brother Incorporated is renamed Wyeth Laboratories.

1943 SMA Corporation, a highly respected nutrition firm, joins Wyeth Laboratories.

1943 AHP merges six companies into the Wyeth company, including Reichel Laboratories, Gilliland Laboratories, Bartos Company, Petrolagar Laboratories, The Bovinine Company, and SMA Corporation.

1943 Wyeth Laboratories becomes one of the first firms to produce penicillin commercially.

1944 Wyeth International Limited is formed, consolidating the overseas marketing and sales of Wyeth products.

1952 A new Wyeth antibiotic facility is built in West Chester, Pennsylvania.

1957 Whitehall Pharmacal Company, an original member of AHP, becomes Whitehall Laboratories.

1963 Wyeth introduces the first oral form of a live trivalent poliovirus vaccine in the United States.

1968 Ovral® (norgestrel and ethinyl estradiol tablets), Wyeth's first oral contraceptive, is released. (Please see Important Warning and Prescribing Information.)

1968 Wyeth waives the patent royalties on its bifurcated needle, aiding the delivery of 200 million smallpox vaccinations per year and helping achieve the worldwide eradication of smallpox by 1980.

1975 Lo/Ovral® (norgestrel and ethinyl estradiol tablets) is released by Wyeth and becomes the most frequently prescribed low-dose contraceptive in the U.S. (Please see Important Warning and Prescribing Information.)

1982 AHP acquires Sherwood Medical, capturing a share of the growing medical devices market.

1984 Whitehall markets Advil®, the first nonprescription ibuprofen in the U.S.

1985 Ives Laboratories merges with Wyeth.

1987 Amalgamation of Wyeth and Ayerst forms Wyeth-Ayerst.

1987 AHP buys Bristol-Myers Company's animal health division and assimilates the new business into Fort Dodge (now Fort Dodge Animal Health).

1988 Wyeth introduces the first Haemophilus b conjugate vaccine licensed in the United States for use in infants for protection against bacterial meningitis.

1988 AHP acquires Parke-Davis Animal Health Products, becoming the third-largest animal health products manufacturer in the United States.

1989 AHP acquires A.H. Robins.

1991 Wyeth introduces the first diphtheria/tetanus/acellular pertussis (DTaP) vaccine available in the United States.

1993 Wyeth establishes Women's Health Research Institute®, the first such pharmaceutical laboratories dedicated entirely to women's health.

1993 Wyeth launches the first serotonin and norepinephrine reuptake inhibitor for effective treatment of depression.

1994 AHP acquires American Cyanamid, and, as a result, AHP holds the majority interest in Immunex Corporation.

1996 AHP sells its food business, American Home Foods, to Hicks, Muse, Tate & Furst Incorporated.

1996 AHP reaches an agreement with Solvay SA to purchase Solvay's worldwide animal health business and combines it with Fort Dodge Animal Health.

1996 AHP acquires Genetics Institute, a leading biopharmaceutical firm.

1997 AHP sells Storz Instrument Company to Bausch & Lomb Incorporated.

1998 AHP completes the divestiture of its Sherwood-Davis & Geck business to Tyco International Ltd.

1998 Wyeth-Lederle acquires Apollon, Inc.

1998 Immunex drug Enbrel® (etanercept) is recommended for approval by the FDA Advisory Committee for treatment of rheumatoid arthritis.(Please see Important Warning and Prescribing Information.)

1998 AHP sells Quinton Instruments to a strategic investment group formed by W.R. Hambrecht & Company, Hewlett-Packard Company, and Zymed Corporation.

1998 Whitehall-Robins Healthcare acquires assets of Solgar Vitamin and Herb Company, Inc. and related affiliates.

1999 Wyeth announces FDA approval for Sonata® (zaleplon) and Rapamume® (sirolimus). (Please see Important Warning and Prescribing Information for Rapamune.)

2000 Wyeth receives FDA approval of Prevnar®, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), ReFacto® Antihemophilic Factor (Recombinant), and Mylotarg®s (gemtuzumab ozogamicin for Injection). (Please see Important Warning and Prescribing Information for Mylotarg.)

2000 AHP completes the sale of its Cyanamid Agricultural Products business to BASF Aktiengesellschaft, reflecting its focus on its pharmaceutical, biotechnology, consumer health care, and animal health care products businesses.

2001 AHP agrees to sell its 41% share in Immunex Corporation to Amgen, Inc. for cash and an 8% interest in Amgen.

2002 AHP changes its name to Wyeth to reflect its role as a global research-driven pharmaceutical company committed to solving the world's health problems through leading-edge biotechnology.

Wyeth, headquartered in Madison, New Jersey, is one of the largest research-based pharmaceutical and health care products companies in the world. Wyeth is dedicated to solving the world's most critical health problems through research and development, spending approximately $1.9 billion in overall R&D in 2001. With annual sales of $14.1 billion in 2001 and products sold in more than 140 countries, Wyeth is truly a global health care leader.

The divisions of Wyeth are:
Wyeth Pharmaceuticals
Wyeth Research
Wyeth Consumer Healthcare
Fort Dodge Animal Health
Wyeth Pharmaceuticals comprises of prescription products, vaccines, and nutritionals. Wyeth Research includes Wyeth BioPharma, the organization within Wyeth responsible for deployment and manufacturing of recombinant protein biopharmaceuticals.
In addition, Wyeth owns Scientific Protein Laboratories, Inc., a leading supplier of high-quality bulk pharmaceuticals worldwide. Core products include pancreatic enzymes, heparin, and thrombin.
Products under development include new treatments for cancer, asthma, rheumatoid arthritis, inflammatory diseases, infectious diseases, and cardiovascular diseases.